Bevacizumab (Human) ELISA Kit
Size: 96 Well
Application: Therapeutic drug monitoring in human serum or plasma.
A Sandwich ELISA kit for the quantitative measurement of Bevacizumab in human serum or plasma.
Bevacizumab is a recombinant human IgG1 monoclonal antibody specific for all human vascular endothelial growth factor-A (VEGF-A) isoforms. The humanized anti-VEGF monoclonal antibody, bevacizumab, has been approved by the FDA as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy. The pharmacokinetic properties of bevacizumab in several species have been previously described and are consistent with a typical humanized monoclonal antibody. It was shown in the literature that the surveillance of circulating concentration during maintenance therapy represents a direct and/or indirect factor for some other side effects. Identification of biomarkers for (non-)response and risk factors for adverse drug reactions that might be related to serum concentrations and maintaining the effective concentration of Bevacizumab in order to potentially avoid some side effects with a reliable method might be beneficial.96Trace’s Bevacizumab ELISA kit has been developed for specific quantification of Bevacizumab concentration in human serum or plasma with high sensitivity and reproducibility.
| Assay Format | Sandwich ELISA |
| Species Reactivity | Human |
| Sample Type | Human serum and plasma |
| Detection Method | Absorbance (450 nm) |
| Detection Wavelength | 450 nm |
| Kit Size | 96 Well |
| Detection Range | 30 - 1000 ng/ml |
| Sensitivity | 30 ng/ml |
This ELISA kit is used for quantitative measurement of Bevacizumab in human serum and plasma
| Storage | +4°C |
| Shipping | Gel Pack |
| Shelf Life | 12 Months |
| Catalog Number | TRC-00141 |
| Analyte / Target | Bevacizumab |
| Alternate Name | VPF, VEGF, MVCD1, VEGFA, CAS 216974-75-3 |